CMND
Clearmind Medicine Inc.
Price Chart
Latest Quote
$3.07
-0.07 (-2.23%)
Current Price
| Previous Close | $3.14 |
| Open | $3.15 |
| Day High | $3.44 |
| Day Low | $2.94 |
| Volume | 1,274,451 |
Stock Information
| Shares Outstanding | 1.49M |
| Total Debt | $86K |
| Cash Equivalents | $13.59M |
| Net Income | $-7.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.56M |
| EPS (TTM) | $-175.92 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-12.56M |
| Income | $-7.90M |
| Book/sh | $75.44 |
| Cash/sh | $9.15 |
Financial Ratios
| Quick Ratio | 4.73 |
| Current Ratio | 4.79 |
| Debt/Eq | 0.74 |
Returns & Margins
| ROA | -51.35% |
| ROE | -114.61% |
Ownership
| Insider Ownership | 0.14% |
| Institutional Ownership | 190.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.04 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.07 |
| SMA50 | $5.52 |
| SMA200 | $111.62 |
| RSI | 41.47 |
| ATR | 0.5399 |
| Shares Float | 302K |
| Short Float | 3.98% |
| Short Ratio | 0.02 |
| Rel Volume | 0.27 |
Performance History
| Week | -8.08% |
| Month | +30.08% |
| Quarter | -53.13% |
| 6 Months | -88.28% |
| YTD | -84.57% |
| Year | -99.09% |
| 3 Years | -99.95% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.07 | 1,281,700 |
| 2026-06-17 | $3.14 | 122,600 |
| 2026-06-16 | $3.14 | 1,687,700 |
| 2026-06-15 | $3.37 | 103,000 |
| 2026-06-12 | $3.34 | 162,200 |
| 2026-06-11 | $3.34 | 148,600 |
| 2026-06-10 | $3.20 | 120,500 |
| 2026-06-09 | $3.39 | 254,700 |
| 2026-06-08 | $3.79 | 1,027,200 |
| 2026-06-05 | $3.98 | 41,850,600 |
| 2026-06-04 | $2.91 | 126,200 |
| 2026-06-03 | $2.91 | 173,900 |
| 2026-06-02 | $2.92 | 261,200 |
| 2026-06-01 | $3.17 | 1,072,800 |
| 2026-05-29 | $3.58 | 44,924,800 |
| 2026-05-28 | $2.45 | 67,300 |
| 2026-05-27 | $2.48 | 70,400 |
| 2026-05-26 | $2.59 | 330,900 |
| 2026-05-22 | $2.26 | 106,500 |
| 2026-05-21 | $2.46 | 183,000 |
| 2026-05-20 | $2.52 | 199,320 |
| 2026-05-19 | $2.36 | 544,740 |
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
đ° Latest News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-06-08T18:41:14ZWhy Did CMND Stock Jump 40% Today?
Stocktwits âĸ 2026-05-29T15:04:18Z
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-05-21T10:49:45Z
Tirzepatide Combination Study Expands Clearmindâs Obesity Therapy Strategy (CMND)
InvestorsHub âĸ 2026-05-18T15:17:29Z
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
MT Newswires âĸ 2026-04-24T14:19:44ZPsychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness
MT Newswires âĸ 2026-04-20T11:23:51ZTrump Trade: President to sign order on psychedelic used for PTSD
TipRanks âĸ 2026-04-17T21:56:03Z
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
TipRanks âĸ 2026-03-06T15:15:45Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-12-02T15:30:17ZClearmind Medicine Signs Deal to Raise Up to $10 Million Through Convertible Notes
MT Newswires âĸ 2025-09-19T13:14:20Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $19,537 | $36,161 | $10,894 | $14,417 |
| Total Expenses | $5,667,177 | $5,744,925 | $6,303,434 | $6,251,431 |
| Other Income Expense | $1,767,268 | $633,150 | $-2,359,205 | $-599,161 |
| Other Non Operating Income Expenses | $-209,196 | - | - | - |
| Net Non Operating Interest Income Expense | $113,371 | $235,063 | $59,174 | $-14,417 |
| Interest Expense Non Operating | $19,537 | $36,161 | $10,894 | $14,417 |
| Operating Expense | $5,667,177 | $5,744,925 | $6,303,434 | $6,251,431 |
| General And Administrative Expense | $3,572,237 | $4,322,029 | $4,721,909 | $3,102,203 |
| Total Other Finance Cost | - | - | $-59,174 | $10,593 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net Interest Income | $113,371 | $235,063 | $59,174 | $-14,417 |
| Interest Income | $132,908 | $271,224 | $70,068 | $0 |
| Normalized Income | $-5,536,977 | $-5,792,856 | $-7,205,314 | $-6,452,747 |
| Net Income From Continuing And Discontinued Operation | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net Income Common Stockholders | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net Income | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net Income Including Noncontrolling Interests | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net Income Continuous Operations | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Pretax Income | $-3,786,538 | $-4,876,712 | $-8,603,465 | $-6,865,009 |
| Interest Income Non Operating | $132,908 | $271,224 | $70,068 | $0 |
| Operating Income | $-5,667,177 | $-5,744,925 | $-6,303,434 | $-6,251,431 |
| Depreciation Amortization Depletion Income Statement | $38,415 | $40,088 | $37,296 | $68,237 |
| Depreciation And Amortization In Income Statement | $38,415 | $40,088 | $37,296 | $68,237 |
| Depreciation Income Statement | $38,415 | $40,088 | $37,296 | $68,237 |
| Special Income Charges | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-303.50 | $-678.00 | $-5679.08 | $-63440.20 |
| Basic EPS | $-303.50 | $-678.00 | $-5679.08 | $-63440.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $296,470 | $94,972 | $-943,682 | $-157,040 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,694,096 | $-5,422,629 | $-6,175,856 | $-6,168,364 |
| Total Unusual Items | $1,976,464 | $633,150 | $-2,359,205 | $-599,161 |
| Total Unusual Items Excluding Goodwill | $1,976,464 | $633,150 | $-2,359,205 | $-599,161 |
| Reconciled Depreciation | $49,369 | $51,072 | $57,510 | $83,067 |
| EBITDA (Bullshit earnings) | $-3,717,632 | $-4,789,479 | $-8,535,061 | $-6,767,525 |
| EBIT | $-3,767,001 | $-4,840,551 | $-8,592,571 | $-6,850,592 |
| Diluted Average Shares | $12,709 | $7,750 | $1,518 | $109 |
| Basic Average Shares | $12,709 | $7,750 | $1,518 | $109 |
| Diluted NI Availto Com Stockholders | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Tax Provision | $70,445 | $377,966 | $17,372 | $29,859 |
| Gain On Sale Of Security | $1,976,464 | $633,150 | $-2,359,205 | $-599,161 |
| Research And Development | $2,056,525 | $1,382,808 | $1,544,229 | $3,080,991 |
| Selling General And Administration | $3,572,237 | $4,322,029 | $4,721,909 | $3,102,203 |
| Other Gand A | $2,513,218 | $2,816,370 | $4,076,295 | $1,914,046 |
| Insurance And Claims | $268,740 | $329,278 | $364,059 | $149,537 |
| Salaries And Wages | $790,279 | $1,176,381 | $281,555 | $1,038,620 |
| Impairment Of Capital Assets | - | - | $0 | $0 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,095,224 | $2,999,226 | $864,162 | $-1,236,262 |
| Total Assets | $6,083,052 | $7,255,414 | $5,953,288 | $826,415 |
| Total Non Current Assets | $135,334 | $167,175 | $158,712 | $391,722 |
| Other Non Current Assets | $20,560 | $7,186 | $37,675 | $14,653 |
| Goodwill And Other Intangible Assets | $97,372 | $108,326 | $119,310 | $130,264 |
| Current Assets | $5,947,718 | $7,088,239 | $5,794,576 | $434,693 |
| Prepaid Assets | $39,940 | $44,161 | $40,403 | $14,245 |
| Receivables | $322,313 | $180,877 | $240,322 | $97,921 |
| Other Receivables | $35,825 | $49,038 | $104,320 | $50,933 |
| Cash Cash Equivalents And Short Term Investments | $5,585,465 | $6,863,201 | $5,513,851 | $322,527 |
| Cash And Cash Equivalents | $3,923,058 | $6,573,813 | $5,427,739 | $128,777 |
| Non Current Deferred Assets | - | - | $0 | $198,173 |
| Other Intangible Assets | - | - | - | $177,797 |
| Cash Financial | - | - | - | $175,768 |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $1,778,866 | $53,142 | $0 | $38,390 |
| Long Term Debt And Capital Lease Obligation | $0 | $16,416 | $0 | - |
| Current Debt And Capital Lease Obligation | $1,778,866 | $36,726 | - | $38,390 |
| Current Debt | $1,760,066 | - | - | - |
| Other Current Borrowings | $1,760,066 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,890,456 | $4,147,862 | $4,969,816 | $1,932,413 |
| Total Non Current Liabilities Net Minority Interest | $0 | $16,416 | $0 | $0 |
| Current Liabilities | $4,890,456 | $4,131,446 | $4,969,816 | $1,932,413 |
| Other Current Liabilities | $2,369,195 | $3,519,702 | $4,310,379 | $290,569 |
| Payables And Accrued Expenses | $742,395 | $575,018 | $659,437 | $1,603,454 |
| Payables | $742,395 | $575,018 | $659,437 | $1,603,454 |
| Accounts Payable | $682,163 | $526,056 | $617,004 | $1,396,960 |
| Equity | ||||
| Common Stock Equity | $1,192,596 | $3,107,552 | $983,472 | $-1,105,998 |
| Total Equity Gross Minority Interest | $1,192,596 | $3,107,552 | $983,472 | $-1,105,998 |
| Stockholders Equity | $1,192,596 | $3,107,552 | $983,472 | $-1,105,998 |
| Other Equity Interest | $2,690,911 | $2,983,287 | $2,641,562 | $2,355,834 |
| Gains Losses Not Affecting Retained Earnings | $-21,250 | $-21,250 | $-21,250 | $-21,250 |
| Other Equity Adjustments | $-21,250 | $-21,250 | $-21,250 | $-21,250 |
| Retained Earnings | $-27,879,724 | $-24,022,741 | $-18,768,063 | $-10,147,226 |
| Other | ||||
| Ordinary Shares Number | $15,807 | $10,662 | $1,518 | $109 |
| Share Issued | $15,807 | $10,662 | $1,518 | $109 |
| Tangible Book Value | $1,095,224 | $2,999,226 | $864,162 | $-1,236,262 |
| Invested Capital | $2,952,662 | $3,107,552 | $983,472 | $-1,105,998 |
| Working Capital | $1,057,262 | $2,956,793 | $824,760 | $-1,497,720 |
| Capital Lease Obligations | $18,800 | $53,142 | $0 | $38,390 |
| Total Capitalization | $1,192,596 | $3,107,552 | $983,472 | $-1,105,998 |
| Capital Stock | $26,402,659 | $24,168,256 | $17,131,223 | $6,706,644 |
| Common Stock | $26,402,659 | $24,168,256 | $17,131,223 | $6,706,644 |
| Long Term Capital Lease Obligation | $0 | $16,416 | $0 | - |
| Current Capital Lease Obligation | $18,800 | $36,726 | $0 | $38,390 |
| Dueto Related Parties Current | $60,232 | $48,962 | $42,433 | $206,494 |
| Net PPE | $17,402 | $51,663 | $1,727 | $48,632 |
| Gross PPE | $17,402 | $51,663 | $1,727 | $48,632 |
| Buildings And Improvements | $17,402 | $51,663 | $0 | $35,730 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $286,488 | $131,839 | $136,002 | $46,988 |
| Other Short Term Investments | $1,662,407 | $289,388 | $86,112 | $193,750 |
| Accumulated Depreciation | - | - | $-25,584 | $-13,188 |
| Other Properties | - | - | $1,727 | $12,902 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,734,498 | $-4,858,659 | $-6,301,472 | $-3,730,057 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,734,498 | $-4,858,659 | $-6,301,472 | $-3,724,494 |
| Cash Flow From Continuing Operating Activities | $-4,734,498 | $-4,858,659 | $-6,301,472 | $-3,724,494 |
| Operating Gains Losses | $-1,132,200 | $-701,751 | $2,268,157 | $290,569 |
| Investing Activities | ||||
| Investing Cash Flow | $-542,017 | $-238,097 | $-26,228 | $-5,563 |
| Cash Flow From Continuing Investing Activities | $-542,017 | $-238,097 | $-26,228 | $-5,563 |
| Net Other Investing Changes | $-13,498 | $33,803 | $-26,228 | - |
| Capital Expenditure | - | - | - | $-5,563 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $2,192,444 | $11,115,241 | $582,558 |
| Financing Cash Flow | $2,622,543 | $6,254,378 | $11,664,396 | $511,688 |
| Cash Flow From Continuing Financing Activities | $2,622,543 | $6,254,378 | $11,664,396 | $511,688 |
| Net Common Stock Issuance | $0 | $2,192,444 | $11,115,241 | $582,558 |
| Common Stock Issuance | $0 | $2,192,444 | $11,115,241 | $582,558 |
| Cash Dividends Paid | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-42,543 | $-42,587 | $-40,922 | $-70,870 |
| Issuance Of Debt | $2,250,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $3,858 | $5,386 | $2,907 | $14,433 |
| Income Tax Paid Supplemental Data | $229,905 | $306,592 | $12,678 | $0 |
| End Cash Position | $3,923,058 | $6,573,813 | $5,427,739 | $128,777 |
| Beginning Cash Position | $6,573,813 | $5,427,739 | $128,777 | $3,369,798 |
| Effect Of Exchange Rate Changes | $3,217 | $-11,548 | $-37,734 | $-22,652 |
| Changes In Cash | $-2,653,972 | $1,157,622 | $5,336,696 | $-3,218,369 |
| Proceeds From Stock Option Exercised | $415,086 | $4,104,521 | $590,077 | $0 |
| Net Issuance Payments Of Debt | $2,207,457 | $-42,587 | $-40,922 | $-70,870 |
| Net Long Term Debt Issuance | $2,207,457 | $-42,587 | $-40,922 | $-70,870 |
| Long Term Debt Payments | $-42,543 | $-42,587 | $-40,922 | $-70,870 |
| Long Term Debt Issuance | $2,250,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $-528,519 | $-271,900 | $0 | $0 |
| Sale Of Investment | $186,072 | $78,500 | $0 | $0 |
| Purchase Of Investment | $-714,591 | $-350,400 | $0 | $0 |
| Change In Working Capital | $-39,573 | $-130,109 | $-969,032 | $1,236,710 |
| Change In Other Working Capital | $-144,052 | $7,222 | $-167,856 | $200,443 |
| Change In Payables And Accrued Expense | $82,788 | $-198,590 | $-620,421 | $913,303 |
| Change In Prepaid Assets | $4,442 | $-3,690 | $-26,134 | $103,026 |
| Change In Receivables | $17,249 | $64,949 | $-154,621 | $19,938 |
| Other Non Cash Items | $213,054 | $5,386 | $2,907 | $14,433 |
| Stock Based Compensation | $805,890 | $998,918 | $834,813 | $1,207,549 |
| Unrealized Gain Loss On Investment Securities | $-844,500 | $68,624 | $107,638 | $308,187 |
| Deferred Tax | $70,445 | $103,879 | $17,372 | $29,859 |
| Deferred Income Tax | $70,445 | $103,879 | $17,372 | $29,859 |
| Depreciation Amortization Depletion | $49,369 | $51,072 | $57,510 | $83,067 |
| Depreciation And Amortization | $49,369 | $51,072 | $57,510 | $83,067 |
| Amortization Cash Flow | $10,954 | $10,984 | $10,954 | $14,830 |
| Amortization Of Intangibles | $10,954 | $10,984 | $10,954 | $14,830 |
| Depreciation | $38,415 | $40,088 | $46,556 | $68,237 |
| Gain Loss On Investment Securities | $-1,128,586 | $-707,802 | $2,189,986 | $290,569 |
| Net Foreign Currency Exchange Gain Loss | $-3,614 | $6,051 | $78,171 | $0 |
| Net Income From Continuing Operations | $-3,856,983 | $-5,254,678 | $-8,620,837 | $-6,894,868 |
| Net PPE Purchase And Sale | - | $0 | $0 | $-5,563 |
| Purchase Of PPE | - | $0 | $0 | $-5,563 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Change In Payable | - | - | $-788,277 | $1,116,996 |
| Change In Account Payable | - | - | $-620,421 | $915,969 |
| Asset Impairment Charge | - | - | $0 | $0 |
| Interest Paid Cff | - | - | - | $-14,475 |
Fetched: 2026-06-16